Related Experiment Video
Updated: May 3, 2026
Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
Published on: February 3, 2026
A renaissance in therapeutic options for pancreatic neuroendocrine tumors
1From the Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA.
Abstract:
The field of pancreatic neuroendocrine tumors (NETs) has seen a remarkable renaissance in recent years with exponential increases in published research, clinical trials, and U.S. Food and Drug Administration (FDA)-approved treatments. Surgical resection remains the foundation for management of locoregional disease. However, for patients with advanced disease, novel therapeutic options have emerged. Two separate randomized placebo-controlled studies have shown prolonged progression-free survival (PFS) with everolimus or sunitinib. Future studies are designed to answer questions about the role of somatostatin analogs as antiproliferative agents, combinations of biologic therapies, and new cytotoxic chemotherapy backbones.
Insights
Recent advances in pancreatic neuroendocrine tumors (NETs) include new FDA-approved treatments. Novel therapies like everolimus and sunitinib show promise in prolonging progression-free survival for advanced NETs.
Area of Science:
- Oncology
- Translational Research
- Gastroenterology
Background:
- Pancreatic neuroendocrine tumors (NETs) represent a heterogeneous group of neoplasms.
- Significant advancements in research, clinical trials, and FDA-approved treatments have occurred recently.
- While surgery is standard for locoregional NETs, options for advanced disease are expanding.
Purpose of the Study:
- To summarize recent progress in the management of pancreatic neuroendocrine tumors (NETs).
- To highlight novel therapeutic options for advanced NETs.
- To outline future research directions in NET treatment.
Main Methods:
- Review of recent clinical trials and FDA-approved therapies for pancreatic NETs.
- Analysis of data from placebo-controlled studies evaluating targeted agents.
- Discussion of ongoing and planned research in NET therapeutics.
Main Results:
- Everolimus and sunitinib have demonstrated prolonged progression-free survival (PFS) in randomized trials for advanced NETs.
- These targeted therapies represent significant progress beyond traditional treatment modalities.
- The efficacy of these agents underscores the evolving landscape of NET management.
Conclusions:
- The management of pancreatic NETs is rapidly evolving with new treatment options.
- Targeted therapies like everolimus and sunitinib are effective in improving PFS for advanced disease.
- Future research will focus on somatostatin analogs, combination therapies, and novel chemotherapy regimens.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...